Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;23(16):1505-1525.
doi: 10.2174/1389450123666220907144131.

Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms

Chaofeng Xu  1 , Zhongtu Shang  1 , Masoud Najafi  2   3
Affiliations
Review

Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms

Chaofeng Xu et al. Curr Drug Targets. 2022.

Abstract

Fibrosis and pneumonitis are the most important side effects of lung tissue following cancer therapy. Radiotherapy and chemotherapy by some drugs, such as bleomycin, can induce pneumonitis and fibrosis. Targeted therapy and immunotherapy also may induce pneumonitis and fibrosis to a lesser extent compared to chemotherapy and radiotherapy. Activation of lymphocytes by immunotherapy or infiltration of inflammatory cells such as macrophages, lymphocytes, neutrophils, and mast cells following chemo/radiation therapy can induce pneumonitis. Furthermore, the polarization of macrophages toward M2 cells and the release of anti-inflammatory cytokines stimulate fibrosis. Lung fibrosis and pneumonitis may also be potentiated by some other changes such as epithelial-mesenchymal transition (EMT), oxidative stress, reduction/oxidation (redox) responses, renin-angiotensin system, and the upregulation of some inflammatory mediators such as a nuclear factor of kappa B (NF-κB), inflammasome, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS). Damages to the lung vascular system and the induction of hypoxia also can induce pulmonary injury following chemo/radiation therapy. This review explains various mechanisms of the induction of pneumonitis and lung fibrosis following cancer therapy. Furthermore, the targets and promising agents to mitigate lung fibrosis and pneumonitis will be discussed.

Keywords: Chemotherapy; EMT; fibrosis; lung; pneumonitis; radiotherapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aznar M.C.; Duane F.K.; Darby S.C.; Wang Z.; Taylor C.W.; Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010-2015. Radiother Oncol 2018,126(1),148-154 - DOI - PubMed
    1. Nakao S.; Yamaguchi K.; Sakamoto S.; Chemotherapy-associated acute exacerbation of interstitial lung disease shortens survival especially in small cell lung cancer. Anticancer Res 2019,39(10),5725-5731 - DOI - PubMed
    1. Li L.; Mok H.; Jhaveri P.; Anticancer therapy and lung injury: Molecular mechanisms. Expert Rev Anticancer Ther 2018,18(10),1041-1057 - DOI - PubMed
    1. Goodman C.D.; Nijman S.F.M.; Senan S.; A primer on interstitial lung disease and thoracic radiation. J Thorac Oncol 2020,15(6),902-913 - DOI - PubMed
    1. Cho J.Y.; Kim J.; Lee J.S.; Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer 2018,125,150-156 - DOI - PubMed